Tevogen Inc. SEC filings TVGN
Tevogen Inc. has 309 filings in SEC EDGAR's recent list, going back to Jun 10, 2021. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jun 25, 2026 | — |
| EFFECT | Filing | Jun 26, 2025 | — |
| CORRESP | Letter to the SEC | Jun 24, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 24, 2025 | — |
| EFFECT | Filing | May 2, 2025 | — |
| NT 10-K | Filing | Apr 1, 2025 | Dec 31, 2024 |
| NT 10-Q | Filing | Nov 15, 2024 | Sep 30, 2024 |
| EFFECT | Filing | Aug 2, 2024 | — |
| CORRESP | Letter to the SEC | Aug 1, 2024 | — |
| CORRESP | Letter to the SEC | Jul 31, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 30, 2024 | — |
| CORRESP | Letter to the SEC | Jul 29, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 24, 2024 | — |
| CORRESP | Letter to the SEC | Jul 23, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 2, 2024 | — |
| NT 10-Q | Filing | May 16, 2024 | Mar 31, 2024 |
| NT 10-K | Filing | Apr 2, 2024 | Dec 31, 2023 |
| CERT | Filing | Feb 15, 2024 | — |
| 8-A12B | Filing | Feb 14, 2024 | — |
| 25-NSE | Delisting notice | Feb 14, 2024 | — |
| 425 | Filing | Feb 1, 2024 | — |
| 425 | Filing | Jan 31, 2024 | — |
| 425 | Filing | Jan 24, 2024 | — |
| 425 | Filing | Jan 5, 2024 | — |
| EFFECT | Filing | Jan 4, 2024 | — |
| CORRESP | Letter to the SEC | Jan 2, 2024 | — |
| CORRESP | Letter to the SEC | Dec 22, 2023 | — |
| 425 | Filing | Dec 19, 2023 | — |
| 425 | Filing | Dec 18, 2023 | — |
| DEFR14A | Filing | Dec 13, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 4, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 4, 2023 | — |
| PRER14A | Filing | Dec 1, 2023 | — |
| PRER14A | Filing | Nov 27, 2023 | — |
| CORRESP | Letter to the SEC | Nov 27, 2023 | — |
| PRER14A | Filing | Nov 27, 2023 | — |
| CORRESP | Letter to the SEC | Nov 21, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 20, 2023 | — |
| 425 | Filing | Nov 17, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 7, 2023 | — |
| CORRESP | Letter to the SEC | Oct 23, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 11, 2023 | — |
| 425 | Filing | Sep 14, 2023 | — |
| NT 10-Q | Filing | Aug 15, 2023 | Jun 30, 2023 |
| 425 | Filing | Jul 12, 2023 | — |
| 425 | Filing | Jun 29, 2023 | — |
| NT 10-Q | Filing | May 15, 2023 | Mar 31, 2023 |
| NT 10-K | Filing | Mar 31, 2023 | Dec 31, 2022 |
| NT 10-Q | Filing | May 17, 2022 | Mar 31, 2022 |
| NT 10-K | Filing | Apr 1, 2022 | Dec 31, 2021 |
| EFFECT | Filing | Nov 3, 2021 | — |
| CERT | Filing | Nov 3, 2021 | — |
| 8-A12B | Filing | Nov 2, 2021 | — |
| CORRESP | Letter to the SEC | Nov 1, 2021 | — |
| CORRESP | Letter to the SEC | Nov 1, 2021 | — |
| CORRESP | Letter to the SEC | Oct 28, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 28, 2021 | — |
| CORRESP | Letter to the SEC | Oct 26, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 26, 2021 | — |
| CORRESP | Letter to the SEC | Oct 22, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 20, 2021 | — |
| CORRESP | Letter to the SEC | Oct 7, 2021 | — |
| DRS/A | Filing | Aug 17, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 8, 2021 | — |
| DRS | Filing | Jun 10, 2021 | — |
Showing 65 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TVGN (Nasdaq), TVGNW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Warren, NJ
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1860871
- Former names
- Tevogen Bio Holdings Inc. (until Jul 30, 2026); Semper Paratus Acquisition Corp (until Feb 15, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.